Latin America Embraces Hemp-based CBD Oil
November 22nd, 2016
News, Top News
As slow as the United States might be in realizing the medical benefits of cannabidiol (CBD), companies like Medical Marijuana Inc. (OTC Pink: MJNA) have demonstrated they are on the forefront of research, production and distribution of legal cannabis products. Latin American countries have taken a much more progressive stance in endorsing such products and politicians worldwide are quickly realizing that legalizing marijuana could reduce crime and help patients suffering from a variety of conditions. With the global tide turning, this progression will create significant opportunities for companies operating in the burgeoning Latin American cannabis industry.
In this article, we will look at some of the recent cannabis reforms across Latin America and why Medical Marijuana Inc. is well positioned as a leader in the space.
Changing Tide of Legalization
Several Latin American countries have relaxed their laws surrounding cannabinoids, including non-psychoactive cannabidiol (“CBD”).
Mexico’s Supreme Court supported four plaintiffs seeking to legally grow and smoke their own marijuana in a November 2015 decision. Shortly after, Mexico City Mayor Miguel Angel Mancera introduced a bill that would allow patients to legally import medical marijuana. In February 2016 Mexico’s regulatory authority, COFEPRIS, approved the legal import of Real Scientific Hemp Oil-X™ for two young girls suffering from severe epilepsy and the program soon expanded to all qualifying citizens with refractory epilepsy.
Brazil has been a long-time opponent of cannabis legalization, but in April 2014, the country and its regulatory authority ANVISA legalized CBD for therapeutic uses. Currently, the government has approved the import of hemp-based CBD oils for epilepsy, Parkinson’s disease, and chronic pain, including migraine headaches. Patients with a doctor’s prescription and approved import documentation can legally purchase Real Scientific Hemp Oil™ products from HempMeds Brazil – an affiliate of Medical Marijuana Inc.
Chile approved a measure legalizing the cultivation and sale of medical marijuana last year. Since then, it has opened the largest medical marijuana farm in Latin America and passed legislation to authorize the cultivation and sale of medical marijuana to nearly 4,000 patients. Chilean President Michelle Bachelet also signed a measure to remove marijuana from a list of dangerous drugs and allow medical marijuana to be sold in pharmacies.
Medical Marijuana Inc. is on the Forefront
Medical Marijuana Inc. is well positioned within the market as the developer of Real Scientific Hemp Oil – or RSHO™ – which is billed as the finest, most consistent, and 100% natural hemp-based CBD oil in the world.
Many patients have already experienced success with RSHO™ in treating conditions like epilepsy. For example, Anny Fischer suffered from a rare form of genetic epilepsy called CDKL5, which caused more than 300 seizures per day. After reading Harper Howard’s story, the Brazilian child’s family petitioned the government to import RSHO™ CBD oil, which significantly reduced her seizures and enabled her to live a normal life again.
View a short movie about the Fischer family’s experience.
Over the past year, the company has generated more than $1.5 million in revenue from the sale of RSHO™ and other products. The rapid expansion of legalization measures across Latin America, as well as the expansion of included medical indications, opens the door to significant revenue growth over the coming quarters.
Medical Marijuana Inc. also provides shareholders with exposure to its other portfolio companies like HempMeds, Dixie Botanicals, Kannaway and CanChew Biotechnologies. Further, the company has invested into two upcoming early-stage biotech enterprises, including AXIM Biotechnologies (OTCQB: AXIM) where MJNA owns a 45% stake.
The company looks forward to leveraging this experience in the United States as cannabinoids become more widely accepted. While the FDA doesn’t allow specific medical claims to be made, researchers have demonstrated a wide variety of potential benefits for cannabinoids across conditions ranging from Alzheimer’s disease to certain types of cancers. The ongoing progress made by researchers could eventually make way for these kinds of claims to be made.
Medical Marijuana Inc. (OTC Pink: MJNA) is capitalizing on Latin America’s increasingly open support for cannabinoids. Colombia recently legalized medical cannabis and Uruguay is soon unveiling its recreational cannabis program for citizens. With its existing RSHO™ footprint, the company is reaching thousands of patients around the world with natural botanical hemp-based CBD products.
The company also provides investors with diversified exposure to other parts of the industry, such as AXIM Biotech’s focus on the clinical development of a cannabinoid chewing gum, as well as a new topical application of cannabinoids for atopic dermatitis and psoriasis.
For more information, visit the company’s website at www.medicalmarijuanainc.com.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.